SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series

The preclinical time course of SARS-CoV-2 shedding is not well-described. Understanding this time course will help to inform risk of SARS-CoV-2 transmission. During an outbreak in a congregate setting, we collected paired mid-turbinate nasal swabs for antigen testing and reverse-transcription polyme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2023-03, Vol.41 (11), p.1769-1773
Hauptverfasser: McCormick, David W., Hagan, Liesl M., Salvatore, Phillip P., Magleby, Reed, Lee, Christine, Sleweon, Sadia, Nicolae, Lavinia, Dixon, Tom, Banta, Robert, Ogle, Isaac, Young, Cristen, Dusseau, Charles, Ogden, Charles, Browne, Hannah, Michael Metz, John, Chen, Min-hsin, Solano, Maria I., Rogers, Shannon, Burgin, Alex, Sheth, Mili, Bankamp, Bettina, Tamin, Azaibi, Harcourt, Jennifer L., Tate, Jacqueline E., Kirking, Hannah L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The preclinical time course of SARS-CoV-2 shedding is not well-described. Understanding this time course will help to inform risk of SARS-CoV-2 transmission. During an outbreak in a congregate setting, we collected paired mid-turbinate nasal swabs for antigen testing and reverse-transcription polymerase chain reaction (RT-PCR) every other day from all consenting infected and exposed persons. Among 12 persons tested prospectively before and during SARS-CoV-2 infection, ten of 12 participants (83%) had completed a primary COVID-19 vaccination series prior to the outbreak. We recovered SARS-CoV-2 in viral culture from 9/12 (75%) of participants. All three persons from whom we did not recover SARS-CoV-2 in viral culture had completed their primary vaccination series. We recovered SARS-CoV-2 from viral culture in 6/9 vaccinated persons and before symptom onset in 3/6 symptomatic persons. These findings underscore the need for both non-pharmaceutical interventions and vaccination to mitigate transmission.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2022.11.030